One case report described loss of the hypophosphatemic phenotype in an ADHR patient during iron supplementation.53 Preliminary data from a pilot clinical trial of oral iron therapy for ADHR indicated normalization of FGF23 and phosphate levels.54 Although this trial is not yet complete, subjects who had previously required calcitriol and phosphate were able to discontinue these as iron normalized. This evidence concerns the gene FGF23 and autosomal dominant hypophosphatemic rickets.